Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 5/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274233 | 0.94 | MEN1 (0.51) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL30733411 | 0.84 | SIGMAR1 (0.46) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL30733430 | 0.83 | TSHR (0.49) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL30733426 | 0.83 | HDAC1 (0.52) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL26969719 | 0.82 | TSHR (0.48) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL25231257 | 0.79 | MEN1 (0.43) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL25274492 | 0.77 | HDAC1 (0.57) | MEN1TSHRKMT2ATACR1NPY5R | |
| SCHEMBL30733438 | 0.77 | NPY5R (0.44) | MEN1ALDH1A1POLBMAPTTSHR | |
| SCHEMBL30733432 | 0.75 | HDAC1 (0.47) | ALDH1A1TSHRTACR1NPY5RHDAC1 | |
| SCHEMBL6026997 | 0.75 | NPY5R (0.58) | TACR1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | MEN1 782/4885ALDH1A1 3737/4885POLB 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.